A Phase 1 Dose Escalation Study Evaluating The Safety And Tolerability Of Pf-06840003 In Patients With Malignant Gliomas
Phase of Trial: Phase I
Latest Information Update: 14 Sep 2017
At a glance
- Drugs PF 6840003 (Primary)
- Indications Glioblastoma; Glioma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 11 Sep 2017 Planned number of patients changed from 92 to 97.
- 24 Jul 2017 Planned number of patients changed from 97 to 92.
- 10 Mar 2017 Time frame of primary end point (Number of participants with disease control) has been changed from Baseline, Week 9 and Week 26 to Baseline, Week 9 and Week 25.